Medical Device Global Market Access

This episode explores how MedTech and IVD companies can overcome the complexities of international expansion. We discuss a unified, technology-driven approach to registering medical devices in over 30 global markets simultaneously, covering everything from initial regulatory strategy and market selection to the role of local representation and AI-powered technical dossier submissions. Key Questions: - How can you enter 30+ global MedTech markets with a single registration process? - What are the critical first steps in developing a global regulatory strategy? - Why is local representation essential for market access in countries like Brazil or South Korea? - How can AI accelerate the creation and submission of your technical dossiers? - What's the key to selecting the most promising international markets for your device? - How do you maintain compliance after your product is approved abroad? - Can one unified approach work for both startups and multinational corporations? Pure Global provides end-to-end regulatory consulting solutions for MedTech and IVD companies, streamlining access to over 30 global markets. We combine local expertise with advanced AI to manage the entire product lifecycle, from regulatory strategy and market selection to technical dossier submission and post-market surveillance. Our unique 'Single Process, Multiple Markets' approach simplifies expansion, saving you time and resources. Whether you're a startup or a multinational, we act as your local representative to ensure a smooth path to commercialization. For expert guidance, visit https://pureglobal.com/, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode breaks down the crucial differences between free and paid resources in the complex world of medical device market access. We explore what you can achieve with publicly available information from regulatory bodies and when it becomes essential to invest in expert services for strategy, submission, and reimbursement to ensure a successful product launch. - What essential regulatory information is available for free? - Are government websites and databases sufficient for building a full market entry strategy? - When does it become critical to invest in paid consulting and local representation? - How can you determine the return on investment for paid market access services? - What are the hidden costs and risks of relying solely on free resources? - Why is navigating reimbursement and Health Technology Assessment (HTA) bodies impossible without expert support? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in over 30 markets with advanced AI tools to streamline global market access, from initial strategy and technical dossier submission to post-market surveillance. Our integrated approach allows a single registration process to unlock multiple markets, saving you time and resources. Whether you are a startup or a multinational enterprise, our solutions are tailored to get your innovations to patients faster. Contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

This episode explores the critical distinction between standalone AI SaaS tools and a fully integrated, service-based approach for MedTech global market access. We dissect why expensive software alone often falls short and how combining advanced AI with on-the-ground human expertise, local representation, and end-to-end regulatory services provides a more efficient and effective path to launching and maintaining products in over 30 international markets. Key Questions: - Is your expensive AI SaaS tool actually accelerating your global market access? - What is the critical gap most standalone software solutions leave for your regulatory team? - How can a single registration process unlock access to over 30 countries? - What does an integrated service model offer that a pure SaaS platform cannot? - Why is local, human expertise still irreplaceable in the age of AI? - How can AI be used to empower a global team rather than just automate a single task? - What should you look for in a true global regulatory partner? Pure Global offers the end-to-end solution discussed in this episode. We don't just sell software; we provide a complete partnership for MedTech and IVD companies. Our approach combines advanced AI for efficiency with the critical expertise of local representatives in over 30 markets. From initial regulatory strategy and technical dossier submission to post-market surveillance, we streamline your entire global market access journey. Let us handle the complexities so you can focus on innovation. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to see the difference.

This episode explores the strategies and regulatory hurdles involved in bringing medical devices to underserved and emerging global markets. We discuss how to leverage existing approvals, the critical role of local representation, and the use of technology to streamline multi-country submissions, focusing on promising regions like Latin America and Southeast Asia. Key Questions: - How can you leverage your existing US or EU approvals to enter new regions? - What are the primary regulatory hurdles in Latin American and Southeast Asian markets? - Why is local representation critical for success in underserved economies? - How can technology streamline submissions for multiple, non-harmonized markets? - What is the first step in identifying the most promising underserved markets for your device? - Is it possible to use a single registration process to access dozens of countries? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI. We help you develop efficient regulatory strategies, act as your local representative in over 30 markets, and use AI to compile technical dossiers for faster submissions. Our integrated approach allows a single registration process to unlock multiple international markets simultaneously. To accelerate your global expansion and access our FREE AI tools and regulatory database, visit us at https://pureglobal.ai or contact our team at [email protected].

This episode explores how Artificial Intelligence is revolutionizing the medical device registration process, breaking down financial barriers and enabling broader global market access. We discuss the shift from costly, manual submissions to an efficient, technology-driven model that allows MedTech companies of all sizes to bring life-saving innovations to patients worldwide. Learn how AI is not just a tool for efficiency but a force for democratizing global healthcare access. Key Questions: - How can AI drastically reduce the cost of medical device registration? - What are the traditional barriers preventing MedTech companies from entering global markets? - How does lowering registration costs impact patient access to life-saving devices? - Can AI help you bring 10 times more products to 10 times more countries? - Which global markets can be navigated using AI-powered regulatory intelligence? - What specific tasks in the regulatory submission process can be automated? - How is technology making global compliance accessible for startups and smaller companies? Pure Global offers end-to-end regulatory solutions for MedTech and IVD companies, leveraging AI and local expertise to accelerate global market access. We help you develop regulatory strategies, compile technical dossiers with advanced AI, and act as your local representative in over 30 markets. Our goal is to make global expansion efficient and affordable, from initial strategy to post-market surveillance. Visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to start your journey.

This episode explores the transformative impact of free AI-powered tools on the medical device industry. We discuss how making regulatory intelligence and global device databases accessible at no cost is breaking down financial barriers, enabling MedTech companies to expand their reach into new international markets more efficiently and affordably. This shift promises to accelerate the availability of life-saving technologies to patients around the world. - How is Artificial Intelligence revolutionizing the MedTech regulatory landscape? - What if you could access global medical device registration databases for free? - Can AI genuinely lower the cost of market entry for life-saving devices? - What specific AI-powered tools are now available to streamline compliance in over 30 markets? - How can your company leverage free AI for device classification and regulatory pathway analysis? - What is the vision behind making core regulatory AI agents completely free? - How does this shift impact market access in regions like South America, Asia, and Africa? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging advanced AI to streamline global market access. We help you identify the best markets, develop efficient regulatory strategies, and use AI to compile and submit technical dossiers. Our integrated approach allows a single registration process to unlock multiple international markets, supported by local experts in over 30 countries. Whether you're a startup or a multinational enterprise, our technology-driven solutions accelerate your time-to-market. Explore our free AI tools and databases at https://pureglobal.ai, visit our website at https://pureglobal.com, or contact us at [email protected].

This episode provides a detailed overview of Colombia's foundational medical device regulation, Decree 4725 of 2005. We explore the critical role of INVIMA, the risk-based classification system, key submission requirements for market approval, and post-market surveillance obligations for MedTech and IVD manufacturers looking to enter the Colombian market. Key Questions - What is Decree 4725 and why is it essential for market access in Colombia? - How does INVIMA classify medical devices based on risk? - What are the core components of a technical dossier for submission in Colombia? - Is a local legal representative required to register a medical device in Colombia? - What are a manufacturer's post-market surveillance responsibilities under Colombian law? - How does Colombia's regulatory framework compare to others globally? - What are the first steps to begin the medical device registration process in Colombia? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies targeting Latin America. We act as your local representative in Colombia, developing efficient regulatory strategies to navigate INVIMA's requirements under Decree 4725. Our experts and advanced AI tools streamline the compilation and submission of your technical dossier, helping you access the Colombian market faster. Whether you are a startup or a multinational, we ensure your market entry and post-market activities are fully compliant. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Mexico's Technovigilance requirements for medical devices under COFEPRIS regulation NOM-240-SSA1-2012. We explore the mandatory post-market surveillance system, including the roles of the Sanitary Registration Holder, adverse event reporting timelines, and the documentation required for registration renewal. We also discuss the significant updates proposed in the draft 2024 version of the standard, which will impact software devices and distributor obligations. - What is Technovigilance and why is it mandatory for medical devices in Mexico? - Who is responsible for reporting adverse events to COFEPRIS? - What are the specific reporting deadlines for serious and non-serious incidents? - How does post-market surveillance impact the 5-year renewal of your sanitary registration? - What is the function of a Mexico Registration Holder (MRH) in the Technovigilance process? - What key changes are introduced in the draft PROY-NOM-240-SSA1-2024? - Will Software as a Medical Device (SaMD) be covered under the new Technovigilance rules? - What are the core components of a compliant Technovigilance unit? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Mexico, managing your registration and Technovigilance obligations. Our experts develop efficient regulatory strategies and use advanced AI to compile technical dossiers, ensuring compliance with bodies like COFEPRIS. Let us help you maintain your market presence with continuous regulatory monitoring and post-market surveillance support. For a seamless path to market, contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools at https://pureglobal.ai.

This episode provides a critical update on Mexico's new mandatory standard for medical device labeling, NOM-137-SSA1-2024. The host breaks down the key changes from the previous 2008 version, including the strict Spanish language requirement, new provisions for electronic labeling and Software as a Medical Device (SaMD), and updated rules for symbols and date formats. We cover the official publication and effective dates, helping manufacturers understand the timeline for compliance to maintain market access in Mexico. - What is the new mandatory labeling standard for medical devices in Mexico? - When does NOM-137-SSA1-2024 officially come into effect? - Are English labels still acceptable in Mexico under the new regulation? - How does the new standard address electronic labeling and Software as a Medical Device (SaMD)? - What are the specific requirements for displaying expiration dates and using symbols? - What happens if my device labeling is not compliant by the deadline? - How does this 2024 update differ from the previous NOM-137-SSA1-2008? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We streamline global market access using a blend of local expertise and advanced AI. Whether you're navigating Mexico's new NOM-137 standard or expanding into any of our 30+ markets, our team can help with regulatory strategy, technical dossier submission, and post-market surveillance. Our technology-driven approach ensures efficiency and accuracy, helping you get to market faster. Explore our services at https://pureglobal.com, contact us at [email protected], or access our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Mexico's mandatory Good Manufacturing Practices (GMP) standard, NOM-241-SSA1-2021. The host breaks down the key requirements for medical device manufacturers, including the implementation of a Quality Management System, risk management protocols, and alignment with ISO 13485. We discuss the standard's scope, its effective date, and the practical implications for companies seeking to enter or remain compliant in the Mexican market. Key Questions - What is NOM-241-SSA1-2021 and why is it critical for the Mexican market? - How does this standard impact the entire lifecycle of a medical device? - What are the core requirements of a compliant Quality Management System under NOM-241? - How does NOM-241 align with the international ISO 13485 standard? - Are you prepared for a GMP inspection by Mexican authorities? - What documentation is essential for demonstrating compliance? - When did this mandatory standard become fully effective? - Does this regulation affect foreign manufacturers importing into Mexico? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We help you develop efficient regulatory strategies, compile technical dossiers, and act as your local representative in over 30 markets, including Mexico. Our technology-driven approach ensures you navigate complex standards like NOM-241 with confidence. For assistance with your market access needs, visit us at https://pureglobal.com, contact [email protected], or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Mexico's medical device regulations, focusing on the Reglamento de Insumos para la Salud. We explore the role of the regulatory authority, COFEPRIS, the risk-based device classification system, and the available registration pathways, including the Standard and Equivalency routes. The host also covers the crucial updates from the 5th edition of the Mexican Pharmacopoeia's supplement, which became effective in July 2023. - What is the primary regulation for medical devices in Mexico? - How does COFEPRIS classify medical devices based on risk? - What is the difference between the Standard and Equivalency registration routes? - Which foreign approvals can be used to expedite registration in Mexico? - What key changes were introduced in the July 2023 regulatory update? - What are the documentation and language requirements for a submission? - Why is a Mexico Registration Holder (MRH) necessary for foreign manufacturers? - What is the role of the NOM-241 standard in Mexico's QMS requirements? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative in over 30 markets, including Mexico, developing efficient regulatory strategies and using AI to compile and submit technical dossiers. Our services ensure your products meet all local standards for a faster path to market. Contact us at [email protected], visit our website at https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to learn how we can accelerate your global expansion.

This episode provides a comprehensive overview of Mexico's foundational health regulation, the Ley General de Salud, and its impact on medical device market access. We explore the role and authority of the regulatory body, COFEPRIS, and break down the key requirements manufacturers must meet, from pre-market registration and GMP compliance to post-market technovigilance and import controls. Key Questions - What is the Ley General de Salud and why is it critical for MedTech companies? - How does COFEPRIS regulate medical devices in Mexico? - What are the essential components of Mexico's regulatory framework for medical devices? - Are foreign manufacturers required to have a local representative in Mexico? - What are Norma Oficial Mexicana (NOMs) and how do they apply to manufacturing? - What is "technovigilance" and what are the post-market requirements? - Does Mexico have a risk-based classification system for medical devices? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with a unique blend of local expertise and advanced AI tools. Our Market Access & Registration services help you identify the best markets, develop efficient regulatory strategies, and prepare technical dossiers for submission. Acting as your local representative in over 30 markets, we manage the entire registration process to get your product approved and ready for sale. Visit https://pureglobal.com/, email us at [email protected], or explore our FREE AI tools and database at https://pureglobal.ai to learn more.

This episode provides a detailed analysis of Brazil's RDC 687/2022, a critical regulation from ANVISA governing Good Manufacturing Practices (GMP) certification for Class III and IV medical device manufacturers. We explore the key requirements, audit procedures, and documentation needed to secure the mandatory CBPF certificate, highlighting the changes from the previous RDC 183/2017 and what international manufacturers must do to successfully enter the Brazilian market for high-risk devices. Key Questions: - What is ANVISA's RDC 687/2022 and who does it apply to? - How does this regulation impact manufacturers of Class III and IV medical devices? - What are the mandatory steps to obtain GMP certification in Brazil? - What replaced the previous RDC 183/2017 regulation, and when? - How long is the Brazilian GMP certificate valid for? - What kind of documentation is required for the submission to ANVISA? - Why is this certification a prerequisite for market entry in Brazil? Navigating regulations like Brazil's RDC 687/2022 is where Pure Global excels. We offer end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and AI tools. Our team acts as your local representative in Brazil and over 30 other markets, developing efficient pathways for ANVISA approval and using AI to compile technical dossiers. We manage submissions and ensure ongoing compliance so you can access markets faster. For comprehensive support, contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Brazil's key technovigilance regulations for medical devices, RDC 67/2009 and RDC 551/2021. We explore the mandatory requirements for post-market surveillance, the critical role of the Brazilian Registration Holder (BRH), and the specific, strict timelines set by ANVISA for reporting adverse events, malfunctions, and field safety corrective actions to ensure continued compliance and patient safety in the Brazilian market. - What is the primary purpose of Brazil's RDC 67/2009? - How does RDC 551/2021 complement the requirements of RDC 67/2009? - Who is ultimately responsible for technovigilance reporting to ANVISA? - What are the specific reporting timelines for different types of adverse events? - What happens if a serious adverse event occurs outside of Brazil with a device sold in the country? - Are malfunctions that haven't caused harm required to be reported? - Why is a proactive post-market surveillance system crucial for market access in Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Brazil, ensuring your post-market surveillance and technovigilance systems are fully compliant with ANVISA's requirements. Our experts manage adverse event reporting and field safety corrective actions, navigating complex timelines so you can maintain market presence securely. Leveraging advanced AI, we make compiling and managing technical documentation efficient and accurate. For expert guidance on entering and staying in the Brazilian market, contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode explores Brazil's key regulation for medical device and IVD manufacturers, ANVISA RDC 665/2022. We break down the Brazilian Good Manufacturing Practices (BGMP) requirements, its alignment with international standards like ISO 13485, its replacement of the former RDC 16/2013, and its crucial integration with the Medical Device Single Audit Program (MDSAP) for streamlining market entry. Key Questions: - What is ANVISA RDC 665/2022 and who does it apply to? - How does this resolution change the requirements from the old RDC 16/2013? - What are the core principles of Brazilian Good Manufacturing Practices (BGMP)? - How does RDC 665/2022 align with global standards like ISO 13485 and FDA QSR? - Can an MDSAP audit be used to achieve BGMP certification in Brazil? - What are the key dates associated with the implementation of RDC 665/2022? - Why is BGMP compliance a mandatory step for selling medical devices in Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI to streamline global market access. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using AI to compile and submit technical dossiers. Our integrated approach allows a single registration process to access multiple markets, supported by our global reach and technology-driven efficiency. Whether you are a startup or a multinational, we provide scalable solutions to get your innovations to market faster. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai/.

This episode provides a detailed analysis of Brazil's new IVD regulation, ANVISA RDC 830/2023, which was implemented in June 2024. We explore the critical changes to risk classification systems, which align with international standards and result in the up-classification of many devices. The discussion covers the impact on regulatory pathways, technical documentation, and labeling, offering essential insights for manufacturers to ensure continued market access in Brazil. - What is Brazil's new RDC 830/2023 for IVD devices? - When did this new ANVISA regulation take effect? - How does the new risk classification system impact IVD manufacturers? - Why are many IVD devices being moved to higher risk classes in Brazil? - What is the difference between the 'notificação' and 'registro' pathways? - What are the new labeling requirements under RDC 830/2023? - How should your company prepare for these regulatory changes in Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. With Brazil's new RDC 830/2023 creating significant shifts, our local experts and advanced AI tools are essential for navigating the updated risk classifications and registration requirements. We act as your local representative in over 30 markets, including Brazil, developing efficient regulatory strategies and compiling technical dossiers to ensure compliance and speed to market. Let us help you navigate this changing landscape. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode provides a detailed overview of Brazil's pivotal medical device regulation, ANVISA RDC 751/2022, which became effective in March 2023. We explore its comprehensive framework, including the four-tier risk classification system, the distinct pathways for notification and registration, and its alignment with international standards like the IMDRF Table of Contents. The host also discusses modernized rules for Software as a Medical Device (SaMD) and what these significant changes mean for manufacturers seeking market access in Brazil. - What is ANVISA's RDC 751/2022 and why is it critical for device manufacturers? - How does Brazil classify medical devices by risk under the new regulation? - What is the difference between the 'notificação' and 'registro' pathways? - How does RDC 751/2022 align with global standards like the IMDRF? - Are there new rules for Software as a Medical Device (SaMD) in Brazil? - What previous regulations did RDC 751/2022 replace? - When did this new regulation become effective? - How can manufacturers leverage their existing technical files for Brazilian submission? Pure Global simplifies the complexities of global market access for MedTech and IVD companies. Our experts in Brazil provide end-to-end support for ANVISA registration under RDC 751/2022, from developing a regulatory strategy and compiling technical dossiers to acting as your official in-country representative. By leveraging advanced AI and a deep understanding of local requirements, we help you achieve faster, more efficient market entry. Let us manage the regulatory hurdles so you can focus on innovation. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.

This episode delves into the critical process for medical device manufacturers to regain control of their Singapore market access by transitioning from a distributor-held registration to an independent registrant. We explain why tying your regulatory license to a commercial partner creates business risks and outline the strategic advantages and procedural steps involved in making the switch with Singapore's Health Sciences Authority (HSA). Key Questions: • What is an HSA Registrant and why is it mandatory for selling medical devices in Singapore? • Are you unknowingly locked in with your current Singaporean distributor? • What happens to your product license if you terminate your distributor agreement? • How does appointing an independent representative give you full control over your market access? • What is the official process for changing your Local Authorized Representative with the HSA? • Why can't you simply "transfer" your existing medical device registration to a new entity? • What key document do you need to authorize a new independent registrant? • How does this change impact your ability to work with multiple distributors? • What are the long-term benefits of separating your regulatory and commercial partners? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the critical process of changing a medical device registration holder in Vietnam. We clarify a common misconception: a direct license transfer between holders is not permitted by the Ministry of Health. Instead, manufacturers must navigate a full re-registration process. We outline the steps involved and highlight the significant strategic advantages of appointing an independent registration holder to maintain control and flexibility over your market access. Key Questions: • Thinking of changing your distributor in Vietnam? • Is your medical device registration currently held by your commercial partner? • What happens to your market access if that partnership ends? • Can you simply transfer a device registration from a distributor to a new company in Vietnam? • What is the official process for changing your registration holder with the MOH? • Why is appointing an independent registration holder a smarter long-term strategy? • How can you avoid being locked into an underperforming distributor? • What are the risks of a distributor refusing to cancel an existing registration? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical strategic choice between appointing a distributor versus an independent Designated Marketing Authorization Holder (D-MAH) for medical device registration in Japan. We break down how using an independent D-MAH allows foreign manufacturers to retain ownership of their marketing approvals, providing essential flexibility in distribution strategy, safeguarding confidential information, and ensuring robust regulatory compliance in the Japanese market. Key Questions: • What is the difference between an MAH and a D-MAH in Japan? • Who legally owns your product registration if your distributor is the MAH? • What happens to your market access if you want to switch distributors in Japan? • How can you protect your confidential device information from your commercial partners? • Why is an independent D-MAH a more flexible long-term strategy? • What is the Foreign Special Approval System (FSAS) and how does it help foreign manufacturers? • How does using an independent D-MAH impact your commercial and distribution strategy? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the strategic process of changing a TGA Sponsor for medical devices in Australia. We explore the critical differences between using a distributor as a sponsor versus an independent sponsor, outlining the risks of the former and the long-term benefits of the latter. Learn about the official transfer process, the importance of Manufacturer Evidence, and the key steps to ensure a smooth transition while maintaining market access and regulatory control. Key Questions: • What is the role of a TGA Sponsor in Australia? • Why is using your distributor as a sponsor a potential risk to your business? • How does an independent sponsor give you more control over your market strategy? • What is the official process for transferring a medical device registration to a new sponsor? • What is "Manufacturer Evidence" and why is it crucial for a sponsor transfer? • Are there any TGA fees associated with changing sponsors? • How can you ensure a seamless handover of regulatory responsibilities? • What should be included in a transfer agreement between sponsors? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical process of switching your Indian Authorized Agent (IAA) with the CDSCO, moving from a commercially-tied distributor to an independent regulatory partner. We detail the significant business risks of using a distributor as your agent and provide a step-by-step guide for making the change, including the crucial role of the No-Objection Certificate (NOC). Learn how an independent IAA provides commercial flexibility and secures your long-term market access in India. Key Questions: • What are the primary responsibilities of an Indian Authorized Agent (IAA)? • Why is it risky to appoint your distributor as your legal representative in India? • What is a No-Objection Certificate (NOC) and why is it essential for changing your IAA? • Is it possible to transfer an existing CDSCO import license to a new agent? • What is the official process for appointing a new independent IAA with the CDSCO? • How does an independent IAA grant you more control over your commercial strategy? • What documents are required to prove no changes have been made to the device during the switch? • How can this change protect your business from being held hostage by a commercial partner? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the critical process of transferring ANMAT medical device registration in Argentina from a distributor to an independent holder. We explore the strategic risks of distributor-held registrations, such as commercial lock-in, and provide a clear overview of the transfer process, including the role of the Argentina Authorized Representative (AAR) and the importance of the governing regulation, ANMAT Provision 9688 of 2019. Listeners will learn the necessary steps and key considerations for regaining control of their market access. Key Questions: • Why is letting your distributor own your device registration a major risk in Argentina? • What is an Argentina Authorized Representative (AAR) and how do they provide market flexibility? • Which key ANMAT regulation governs the transfer of registration ownership? • What is the most critical step for ensuring a smooth transfer from your current distributor? • How long does the official ANMAT review process for a registration transfer take? • What crucial clause should be included in all your distributor agreements to protect your registration? • Can you force a distributor to transfer your registration if they refuse? • What are the long-term commercial benefits of using an independent registration holder? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores a crucial, often overlooked aspect of entering the Chilean medical device market: the selection of an in-country registration holder. We detail the significant risks of appointing a distributor as your registration holder with the Instituto de Salud Pública (ISP), including loss of market control and conflicts of interest. The discussion then shifts to the strategic advantages of using an independent, third-party representative, which ensures manufacturers retain full ownership and flexibility over their product registrations and commercial strategy. • Why is choosing your registration holder in Chile a critical strategic decision? • What are the hidden risks of letting your distributor own your product registration? • How can a distributor legally hold your market access hostage? • What is the primary conflict of interest when a distributor manages your regulatory compliance? • How does appointing an independent holder give you complete control over your commercial strategy? • What is the role of the Instituto de Salud Pública (ISP) in medical device registration? • Can you switch distributors easily if they are your registration holder? • How does an independent holder model protect your company's long-term interests? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical risks of allowing a distributor to hold your medical device registration in Peru and outlines the strategic advantages of using an independent Peru Registration Holder (PRH). We discuss how this decision impacts your market control, business flexibility, and long-term security. Learn about the process of transferring registration ownership with DIGEMID and why separating your regulatory representation from your commercial partnerships is essential for success. • What is a Peru Registration Holder (PRH) and why is it mandatory? • Are you putting your market access at risk by letting your distributor hold your DIGEMID registration? • What happens to your device registration if you change distributors in Peru? • How does an independent registration holder give you more control and flexibility? • What is the process for transferring registration ownership from a distributor to an independent holder? • Which key regulations, like Decree No. D.S. 029-2015-SA, govern this change? • Why is selecting the right PRH a critical strategic decision for long-term success in Peru? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical process of transferring a medical device registration holder in Mexico. We uncover the risks of appointing a distributor as your legal representative with COFEPRIS and detail the complex legal steps required for a transfer of rights. Learn why choosing an independent registration holder from the outset is the key to maintaining control over your market access and commercial flexibility in this major Latin American market. Key Questions: • What is a Mexico Registration Holder (MRH) and why are they legally significant? • What are the hidden dangers of letting your distributor own your COFEPRIS registration? • Can you be locked out of the Mexican market by a former distributor? • What is the official "transfer of rights" process for a medical device registration? • What legal documents and cooperation are required from the original registration holder? • Why might a distributor refuse to transfer your registration? • What is the costly alternative to a smooth registration transfer? • How does appointing an independent holder protect your business interests? • Why is separating regulatory ownership from commercial distribution a vital strategy? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical decision of who holds your INVIMA medical device registration in Colombia. We delve into the significant business risks of allowing a distributor to be the registration holder and outline the strategic advantages of using an independent third party. Learn about the process for transferring ownership, the potential pitfalls of an uncooperative distributor, and how to maintain full control over your commercial strategy in this key Latin American market. • What is an INVIMA Registration Holder and why does it critically impact your business? • Are you exposing your company to risk by letting your distributor control your market access? • How does an independent registration holder provide commercial flexibility? • What is the official process for switching your registration holder in Colombia? • What happens if your current distributor refuses to transfer the registration? • Can you work with multiple distributors under a single registration? • How can you avoid being locked into a single commercial partner? • What is the best practice for new companies entering the Colombian market? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into a crucial aspect of the Brazilian medical device market: the role of the Brazil Registration Holder (BRH). We explore the significant differences and long-term consequences of appointing a distributor versus an independent third party to hold your device registration with ANVISA. Learn how to avoid common pitfalls that can limit your commercial flexibility and gain control over your market strategy. • What is a Brazil Registration Holder (BRH) and why is it mandatory? • What are the hidden risks of appointing your distributor as your BRH? • How does using a distributor as a BRH limit your ability to change sales partners? • Why is an independent BRH a more strategic choice for market entry? • What are the benefits of separating regulatory holding from commercial distribution? • What does Brazilian Resolution RDC 102/2016 say about transferring a registration? • How can you protect your intellectual property when registering a device in Brazil? • What is the best strategy to ensure long-term control and flexibility in the Brazilian market? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the pivotal regulatory change in the United Arab Emirates allowing medical device manufacturers to appoint an independent Local Authorized Representative (LAR), decoupling registration from commercial distribution. We analyze the risks of the old distributor-as-LAR model and highlight the strategic advantages of the new system, including enhanced market flexibility, greater control over registrations, and improved business continuity for MedTech companies targeting the UAE. • Why was appointing a distributor as your LAR in the UAE a major business risk? • What specific change did the UAE's Ministry of Health and Prevention (MOHAP) implement regarding in-country representation? • How does an independent LAR give manufacturers more control over their products? • What are the key strategic benefits of separating regulatory compliance from commercial sales? • Can you appoint multiple distributors in the UAE after this change without re-registering your device? • What are the core responsibilities of an independent LAR? • How does this shift affect your ability to enter or scale within the UAE market? • Does the manufacturer or the LAR own the device registration under the new model? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode unpacks a crucial change in Turkey's medical device regulations following its alignment with the EU MDR on June 2, 2021. We explore why foreign manufacturers can no longer use their commercial distributors as their Turkish Authorized Representative (TR-REP). The discussion focuses on the inherent conflict of interest between sales and regulatory compliance, the legal responsibilities of an independent TR-REP, and the necessary steps manufacturers must take to appoint a new representative and update their registrations in the ÜTS database to maintain market access. Key Questions: • Why is using your distributor as your Turkish Authorized Representative (TR-REP) now a significant compliance risk? • What is the fundamental conflict of interest between a distributor's commercial goals and a representative's regulatory duties? • How did Turkey's alignment with the EU MDR on June 2, 2021, fundamentally change the role of the TR-REP? • What are the specific legal responsibilities of an independent TR-REP? • What are the essential steps to transition from a distributor-rep to an independent TR-REP? • How does this regulatory shift affect your device registrations in the Turkish ÜTS database? • What are the potential consequences of failing to appoint an independent TR-REP in Turkey? • Does an independent TR-REP model improve patient safety and post-market surveillance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical strategic decision for medical device manufacturers in Saudi Arabia: moving from a distributor-based Local Authorized Representative (LAR) to an independent one. We delve into the significant risks of tying your SFDA product registrations to a commercial partner and outline the clear benefits and straightforward process for making the switch. Learn how to take control of your market access, enhance your strategic flexibility, and secure your business in the Kingdom. • What are the hidden risks of appointing your Saudi distributor as your regulatory representative? • How can a distributor-LAR relationship hold your market access hostage? • What are the strategic advantages of using an independent, third-party LAR? • Is it difficult to switch from a distributor to an independent LAR in Saudi Arabia? • Do you need your current distributor’s permission to make the change? • Will you lose your existing product registrations (MDMA) if you switch representatives? • What does the SFDA require for a smooth transfer process? • Why is this topic more important than ever for low-risk devices since September 2022? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the critical role of the Swiss Authorized Representative (CH-REP) for medical device manufacturers. We explore the significant regulatory changes that made the CH-REP mandatory and uncover the hidden risks of appointing a commercial distributor for this function. Learn why an independent CH-REP is the more strategic choice for ensuring long-term compliance and commercial flexibility in the Swiss market. • Why did Switzerland become a regulatory "third country" for medical devices on May 26, 2021? • What are the core duties and legal liabilities of a Swiss Authorized Representative (CH-REP)? • What is the fundamental conflict of interest when your distributor is also your CH-REP? • How does tying regulatory compliance to a sales partner limit your commercial freedom? • Is your distributor truly equipped to handle joint liability for your devices? • What makes an independent CH-REP a more robust and flexible long-term solution? • What is involved in the process of switching from a distributor to an independent CH-REP? • Are there still grace periods for appointing a Swiss representative? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical shift for medical device manufacturers from using a distributor as their EU Authorized Representative (EC-REP) to appointing a professional, independent representative in France. We delve into the increased liabilities under the MDR, the inherent conflicts of interest in the distributor model, and the significant commercial and regulatory advantages of partnering with an independent AR for streamlined access to the French and broader EU markets. • Why is using a distributor as your EU Authorized Representative now considered a major risk? • What specific liabilities did the EU MDR place on Authorized Representatives? • How does an independent EC-REP provide greater market flexibility in France and across the EU? • What is the fundamental conflict of interest between a distributor's goals and an AR's duties? • What are the key steps involved in switching from a distributor to an independent AR? • How does this change affect your product labeling and registration? • Why is a formal transfer agreement essential for a smooth transition? • How can an independent AR improve your relationship with competent authorities like France's ANSM? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode details the strategic process for medical device manufacturers to transition from a distributor-based EU Authorized Representative (EC-REP) to an independent one in Germany. We cover the regulatory requirements under MDR Article 12, the importance of the tripartite agreement, and the necessary steps for a smooth handover, including German database updates and labeling changes. • Why is using a distributor as an EC-REP a potential conflict of interest? • What is the first step in terminating an agreement with a distributor-representative? • What is a tripartite agreement and why is it essential for this change? • Which specific details must be included in the handover agreement? • How are post-market surveillance duties handled for devices already on the market? • Which German authority and database are involved in this process? • What are the practical implications for product labeling and packaging? • Do you need to inform your Notified Body about the change in EC-REP? • What are the key benefits of using an independent EC-REP? • How does an independent EC-REP better protect a manufacturer's intellectual property? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Since Brexit, non-UK medical device manufacturers need a UK Responsible Person (UKRP) to access the Great Britain market. While appointing a local distributor for this role is a common shortcut, it creates a significant conflict of interest between sales and regulatory compliance. This episode explores the hidden risks of this approach—from a lack of regulatory expertise to giving a commercial partner leverage over your market access—and makes the case for appointing a specialized, independent UKRP for long-term business security and continuity. • What is the UK Responsible Person (UKRP) and why is it mandatory after Brexit? • Why is appointing a distributor as your UKRP a potential conflict of interest? • How could a distributor's sales focus compromise your regulatory compliance? • Does your distributor possess the necessary expertise to engage with the MHRA? • What happens to your market access if you end your agreement with a distributor who is also your UKRP? • How does using a distributor as your UKRP risk your confidential technical files? • What are the key advantages of appointing a dedicated, independent UKRP? • How does separating regulatory and commercial functions provide business flexibility? • Is your current UKRP strategy built for long-term success or short-term convenience? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical need for non-EU medical device manufacturers to replace their distributor-based EU Authorized Representative (EC-REP) with an independent one, particularly for the Spanish market. We delve into the increased liabilities for EC-REPs under the EU MDR (Regulation (EU) 2017/745), the inherent conflicts of interest when a distributor holds this role, and the clear benefits of partnering with a neutral, compliance-focused representative. Learn the official step-by-step process for making this crucial transition to secure your market access and protect your intellectual property. Key Questions: • Why is using your Spanish distributor as your EU Authorized Representative a major risk under the new MDR? • What specific liabilities does your EC-REP now share with you for defective devices? • How does an independent representative protect your confidential technical documentation from competitors? • What is the official process for changing your EC-REP in Spain? • How does the tripartite agreement work between the manufacturer, the old rep, and the new one? • What are the critical labeling changes you must make when you switch representatives? • Could a conflict of interest with your distributor-rep jeopardize your market access? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores the critical shift for MedTech manufacturers from using distributors to appointing independent Authorized Representatives (EC-REPs) in Italy, driven by the EU's Medical Device Regulation (MDR). We unpack the increased legal liabilities, conflicts of interest, and commercial risks associated with the old model, and explain why an independent AR is now essential for secure and flexible market access. Key Questions: • Why is using your Italian distributor as your EU Authorized Representative a major risk under the new MDR? • What does "jointly and severally liable" mean for your European regulatory partner? • How does the EU MDR create a conflict of interest for a distributor acting as your AR? • Can your distributor legally hold your device registrations hostage if you want to switch partners? • What are the strategic advantages of appointing an independent EC-REP for the Italian market? • How does separating your regulatory and commercial partners improve your business flexibility? • What is the primary role of an Authorized Representative in communicating with the Italian Ministry of Health? • Does your current EU AR agreement protect you from the new liability clauses in Regulation (EU) 2017/745? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the crucial role of the Pemegang Izin Edar, or Local Authorized Representative, for medical device market access in Indonesia. We explore the regulatory requirements mandated by the Ministry of Health, the responsibilities of the license holder, and the critical strategic differences between appointing a distributor versus an independent third party to hold your product registration. Understanding this choice is fundamental to maintaining control and flexibility in this key Southeast Asian market. Key Questions: • What is a "Pemegang Izin Edar" and why is it mandatory for foreign manufacturers in Indonesia? • Who is legally responsible for a medical device on the Indonesian market? • What are the main responsibilities of a Local Authorized Representative? • Should you appoint your distributor as your product license holder? • What are the risks of tying your device registration to a single commercial partner? • How can an independent license holder provide greater market flexibility and control? • What happens if you need to change your local representative in Indonesia? • Which key regulation, established in 2017, governs medical device distribution licenses? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential requirement for medical device manufacturers to appoint a Marketing Authorization Holder (MAH) or Local Authorized Representative to enter the United Arab Emirates market. We explore the role and responsibilities of this local partner as mandated by the Ministry of Health and Prevention (MOHAP), the strategic implications of choosing a distributor versus an independent representative, and the key functions they perform in device registration and post-market surveillance. • What is a Marketing Authorization Holder in the UAE? • Why is appointing a local representative mandatory for foreign medical device manufacturers? • What are the core responsibilities of a UAE-based authorized representative? • Should you appoint your distributor or an independent third party as your local agent? • How does this choice impact your long-term market strategy and flexibility? • What key documentation is managed by the local representative during registration with MOHAP? • How long is a typical medical device registration valid in the UAE? • What role does the representative play in post-market surveillance and vigilance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a detailed overview of the mandatory requirement for medical device manufacturers to appoint a Saudi Authorized Representative (AR) to enter the market in Saudi Arabia. We explore the key responsibilities of the AR, from regulatory submissions with the Saudi Food and Drug Authority (SFDA) to post-market surveillance, and analyze the strategic advantages of appointing an independent AR over a commercial distributor. Key Questions • What is a Saudi Authorized Representative and why is it mandatory for foreign manufacturers? • What are the essential duties an AR performs on behalf of a medical device company? • What are the benefits of choosing an independent AR versus appointing your distributor? • How did the regulations for low-risk medical devices change on September 27, 2022? • What qualifications must a local entity possess to become an SFDA-approved AR? • What is the process for submitting a Medical Device Marketing Authorization (MDMA) via an AR? • Can a manufacturer change their appointed AR without re-registering their products? • What legal documentation is required to formalize the relationship with a Saudi AR? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential role of the Marketing Authorization Holder (MAH) for medical device registration in the Philippines. We explore the regulatory requirements set by the Philippine FDA, the responsibilities of an MAH, and the critical strategic considerations for foreign manufacturers when selecting a local representative. Understanding the distinction between a distributor-as-MAH and an independent MAH is key to maintaining control over your market access and long-term business flexibility. Key Questions: • What is a Marketing Authorization Holder (MAH) and why is it mandatory in the Philippines? • Who is eligible to act as an MAH for medical devices? • What are the legal responsibilities of the MAH after a product is on the market? • Is it a good idea to appoint your distributor as your MAH? • How can your choice of MAH impact your business control and market flexibility? • What is a Certificate of Product Registration (CPR) and why is its ownership so important? • What happens to your device registration if you decide to switch distributors? • How does an independent MAH provide a more secure path to market? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Navigating the Israeli medical device market requires a deep understanding of its unique regulatory landscape. This episode provides a comprehensive overview of the Israel Registration Holder (IRH), a mandatory in-country representative for foreign manufacturers. We explore the IRH's crucial role in liaising with the AMAR (Ministry of Health), their extensive responsibilities from registration to post-market surveillance, and the strategic advantages of appointing an independent holder over a distributor. We also touch on the 2024 regulatory reforms that have streamlined market access. • What is an Israel Registration Holder (IRH) and why is it mandatory? • Who is the regulatory authority for medical devices in Israel? • What are the core responsibilities of an IRH? • Should you appoint your distributor as your IRH? • What are the risks of tying your registration to a commercial partner? • How does an independent IRH protect your intellectual property and market control? • What key qualifications must an IRH possess, such as ISO 9001 certification? • How have the 2024 registration reforms impacted market entry strategy? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential role of the License Holder (ผู้รับใบอนุญาต) for foreign medical device manufacturers entering the Thai market. We explain why appointing a local representative is mandatory under the Medical Devices Act, detailing their key responsibilities which include obtaining an Establishment License, managing product registration with the Thai FDA, and overseeing all post-market surveillance and vigilance activities. We also analyze the critical strategic decision between appointing a distributor versus an independent third-party representative and the long-term commercial implications of that choice. Key Questions • What is a License Holder and why is one mandatory for selling medical devices in Thailand? • Which Thai regulations govern the role of an in-country representative? • What are the primary legal duties of a Local Authorized Representative, from pre-market to post-market? • Should you appoint your distributor as your official License Holder? • What are the commercial risks of tying your product registration to a single distribution partner? • How can an independent representative provide greater control and market flexibility? • What is an Establishment License and how does it relate to product registration? • Who is responsible for vigilance and adverse event reporting to the Thai FDA? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential roles of the Authorized Representative (AR) and Registrant for medical device market access in Malaysia. We clarify the legal requirements under the Medical Device Act 2012 (Act 737), explain the responsibilities of a Malaysian AR, and break down the critical strategic differences between appointing a distributor versus an independent third-party as your representative. Understanding this distinction is key to maintaining control over your device registration and ensuring long-term market flexibility. Key Questions: • What is a Malaysia Authorized Representative (AR)? • Who is considered the "Registrant" for a medical device in Malaysia? • What are the legal responsibilities of an AR according to the Medical Device Act 737? • Why is it risky to appoint a distributor as your Authorized Representative? • How does using an independent AR give manufacturers more control? • What qualifications must an entity have to act as an AR in Malaysia? • Can a manufacturer have more than one AR? • What is the MeDC@St system and who uses it? • How does the AR handle post-market surveillance and vigilance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a detailed overview of the mandatory Registration Number Holder (Tổ chức đứng tên đăng ký) in Vietnam for foreign medical device manufacturers. We explore the critical legal, post-market, and commercial responsibilities assigned to this local entity under the governing regulation, Decree 98/2021/ND-CP, which came into effect on January 1, 2022. Key obligations discussed include post-market surveillance, adverse event reporting, product recalls, price declaration, advertising compliance, and warranty provision. Key Questions: • What is a Registration Number Holder and why is it essential for selling medical devices in Vietnam? • Which key Vietnamese regulation defines the responsibilities of the Registration Number Holder? • What are the holder's primary duties regarding post-market surveillance and traceability? • Who is legally responsible for managing adverse events and product recalls in the Vietnamese market? • How is the price of a medical device controlled and declared to the Ministry of Health? • What are the rules for advertising medical devices in Vietnam? • What are the warranty and service obligations of the Registration Number Holder? • How does the choice of a Registration Number Holder impact a manufacturer's compliance and success? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the single most critical requirement for medical device manufacturers entering the Singaporean market: the local Registrant. We explore the legal framework established by the Health Products Act of 2007, defining the Registrant's non-negotiable role as the in-country representative responsible for product registration, post-market surveillance, and all communication with the Health Sciences Authority (HSA). Listeners will learn about the Registrant's key responsibilities and the strategic implications of choosing between a distributor and an independent third-party representative. Key Questions: • What is the Singapore Health Products Act and how does it affect foreign medical device companies? • Why can't overseas manufacturers register their devices directly with the HSA? • Who is legally qualified to act as a medical device Registrant in Singapore? • What are the core responsibilities of a Registrant, from initial submission to post-market reporting? • How does the Registrant handle adverse events and Field Safety Corrective Actions (FSCAs)? • What is the strategic difference between appointing a distributor versus an independent firm as your Registrant? • How can your choice of Registrant impact your long-term business flexibility and market control? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the essential role of the Authorized Indian Agent (AIA) for medical device companies entering the Indian market. We explore the regulatory framework under the CDSCO, the specifics of the MD-14 and MD-15 forms, and the critical strategic considerations when appointing your in-country representative. • What is an Authorized Indian Agent (AIA) and why is it mandatory in India? • How do Forms MD-14 and MD-15 govern the medical device import license process? • What are the key responsibilities of an AIA beyond the initial registration? • Can a distributor act as an Authorized Indian Agent? • What are the risks of tying your import license to a single commercial partner? • Why is the MD-15 license non-transferable, and what does this mean for your business? • How can you maintain commercial flexibility with multiple distributors? • What qualifications must an entity have to become an AIA? • What is the role of the CDSCO's Medical Device Rules, 2017, in this process? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the mandatory role of the In-China Domestic Agent for foreign medical device manufacturers entering the Chinese market. We explore the legal basis under State Council Order 739, effective June 1, 2021, and detail the agent's critical responsibilities in registration, NMPA communication, post-market surveillance, adverse event reporting, and recall management. Learn why selecting the right agent is a vital strategic decision for ensuring long-term regulatory compliance in China. Key Questions: • What is an In-China Domestic Agent and why is it mandatory for medical device manufacturers? • Which key regulation defines the responsibilities of the agent? • How does the agent facilitate initial product registration and filing with the NMPA? • What are the agent's crucial duties regarding post-market surveillance and adverse event reporting? • Who is responsible for coordinating a product recall in China? • How does the agent act as a communication bridge between the manufacturer and Chinese authorities? • Why is the choice of an agent more than just an administrative step? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the role of the Designated Marketing Authorization Holder (DMAH) for medical device companies entering Japan. We explore the critical differences between an MAH and a DMAH, outlining how the DMAH model allows foreign manufacturers to retain full ownership and control of their product approvals. Listeners will learn about the key responsibilities of a DMAH under the PMD Act, from regulatory submissions to post-market surveillance, and understand the strategic advantages of choosing an independent partner for long-term market success. Key Questions • What is a Designated Marketing Authorization Holder (DMAH) in Japan? • How does a DMAH differ from a standard Marketing Authorization Holder (MAH)? • Why can't foreign manufacturers register their medical devices directly with Japan's PMDA? • What are the core responsibilities of a DMAH for post-market surveillance? • How does appointing a DMAH give you more control over your product's registration? • What is a Foreign Restrictive Authorization Holder (FRAH) and how does it relate to the DMAH? • Should you appoint your distributor as your DMAH? • What are the risks of tying your market approval to a single commercial partner? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the essential role of the Australian Sponsor for medical device companies seeking to enter the Australian market. We explain the legal requirements set by the Therapeutic Goods Administration (TGA), the critical responsibilities of a sponsor, and analyze the significant strategic differences between appointing a distributor versus an independent third-party sponsor. Understand how this key decision impacts your regulatory approvals, market flexibility, and long-term success down under. • What is an Australian TGA Sponsor and why is it a legal necessity? • Who is legally responsible for your medical device once it's on the Australian market? • What are the key post-market surveillance duties of a sponsor? • Should you let your distributor act as your TGA Sponsor? • What are the major risks of tying your device registration to a commercial distributor? • How does an independent sponsor provide greater control over your market access? • What happens to your product registration if you decide to change your distributor? • Why is choosing the right sponsor a critical long-term business decision? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.